ARTICLE | Clinical News
Latanoprostene bunod: Phase III started
February 4, 2013 8:00 AM UTC
Bausch + Lomb began the double-blind, international Phase III LUNAR trial to compare once-daily latanoprostene bunod vs. twice-daily timolol for 3 months in about 393 patients with glaucoma and ocular...